Dr. Agarwal's Eye Hospital Q3 Net Profit Jumps 63%

Dr. Agarwal's Eye Hospital Limited reports strong Q3 performance with net profit rising to ₹170 million from ₹104 million year-on-year, marking significant growth in profitability.

Dr. Agarwal's Eye Hospital Declares Rs 3 Interim Dividend, Reports Quarterly Results

Dr. Agarwal's Eye Hospital Limited's Board of Directors approved unaudited financial results for the quarter and half-year ended September 30, 2025. The company declared an interim dividend of Rs 3 per equity share of Rs 10 each for financial year 2025-26, to be paid by November 29, 2025. The record date for dividend eligibility is November 7, 2025. The Board also approved a proposed scheme of amalgamation with Dr. Agarwal's Health Care Limited, subject to shareholder and regulatory approvals. Additionally, the company completed a preferential issue of 4,32,827 equity shares at Rs 5,270 per share to Dr. Agarwal's Health Care Limited, which was allotted on September 26, 2025. The proceeds from this preferential allotment are temporarily invested in debt mutual funds pending utilization. The company operates in a single segment of eye care related sales and services.

Dr. Agarwal's Eye Hospital Reports Strong Q2 Growth, Declares Interim Dividend

Dr. Agarwal's Eye Hospital announced Q2 results showing significant growth across key metrics. Net profit increased to 193.2 million rupees from 141.5 million rupees year-over-year. Revenue grew to 1.18 billion rupees compared to 1.02 billion rupees in the same period last year. EBITDA rose to 401.1 million rupees from 299 million rupees, with EBITDA margin improving to 34.07% from 29.26%. The company recommended an interim dividend of 3 rupees per share.

Dr. Agarwal's Eye Hospital Approves Merger with Parent Company and Preferential Share Allotment

Dr. Agarwal's Eye Hospital Limited's Board approved a merger scheme with Dr. Agarwal's Health Care Limited through amalgamation by absorption. Under the arrangement, AHCL will issue 23 equity shares for every 2 shares held by the Company's shareholders. The Company will also issue 1,32,827 equity shares to AHCL at ₹5,270 per share through preferential allotment, increasing AHCL's stake from 71.90% to 72.67%. Both companies operate in the eye care hospital business. The merger aims to achieve operational efficiencies, streamlined capital allocation, simplified governance, and shareholder value creation. AHCL had disclosed this merger intention in its IPO prospectus when it listed in February 2025. The Company scheduled its 31st Annual General Meeting for September 24, 2025. All transactions require statutory and regulatory approvals including from stock exchanges, SEBI, shareholders, creditors, and the National Company Law Tribunal.

Dr. Agarwal's Eye Hospital Reports 23% Growth in Q1 Net Profit

Dr. Agarwal's Eye Hospital reported a net profit of 173 million rupees for Q1, representing growth from 141 million rupees in the same period last year. The company's revenue increased to 1.17 billion rupees compared to 1 billion rupees year-over-year. Both profit and revenue metrics showed positive year-over-year growth during the quarter.